Assessing Resistance to First-Line BTK Inhibitor Therapy: The Emergine Role of Testing in CLL

Panelists discuss how they assess patients for resistance to first-line BTK inhibitor therapy in chronic lymphocytic leukemia, emphasizing the importance of clinical evaluation, laboratory testing, and genetic analysis in determining the presence and mechanisms of resistance to guide subsequent treatment decisions.

EP: 1.The Current Treatment Landscape for R/R CLL

EP: 2.Impact of Prior BTKi vs BCL2i Therapy on Treatment Decision-Making in CLL

EP: 3.Key Patient-Specific Factors Guiding Treatment Selection in CLL

EP: 4.Tailoring Treatment Approaches for Rapid vs. Slow Disease Progression in CLL

Now Viewing

EP: 5.Assessing Resistance to First-Line BTK Inhibitor Therapy: The Emergine Role of Testing in CLL

Video content above is prompted by the following:

• How do you assess patients for resistance to first-line BTK inhibitor therapy, and what role does testing play in this evaluation?

Related Videos